NEW YORK, Feb. 1, 2011 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
catalogue:
Personalized Medicine – scientific & commercial
aspects
http://www.reportlinker.com/p0203549/Personalized-Medicine—scientific–commercial-aspects.html
Summary
The aim of personalized medicine or individualized treatment is
to match the right drug to the right patient and, in some cases,
even to design the appropriate treatment for a patient according to
his/her genotype. This report describes the latest concepts of
development of personalized medicine based on pharmacogenomics,
pharmacogenetics, pharmacoproteomics, and metabolomics. Basic
technologies of molecular diagnostics play an important role,
particularly those for single nucleotide polymorphism (SNP)
genotyping. Diagnosis is integrated with therapy for selection of
the treatment as well for monitoring the results.
Biochip/microarray technologies are also important and finally
bioinformatics is needed to analyze the immense amount of data
generated by various technologies.
Pharmacogenetics, the study of influence of genetic factors on
drug action and metabolism, is used for predicting adverse
reactions of drugs. Several enzymes are involved in drug metabolism
of which the most important ones are those belonging to the family
of cytochrome P450. The knowledge of the effects of polymorphisms
of genes for the enzymes is applied in drug discovery and
development as well as in clinical use of drugs. Cost-effective
methods for genotyping are being developed and it would be
desirable to include this information in the patient’s record for
the gui
‘/>”/>
